Navigation Links
NicOx' Naproxcinod ABPM Data Presented at American Heart Association
Date:11/7/2007

hieve statistical significance for DBP (p=0.007).

Blood pressure data were collected in the first phase 3 trial for naproxcinod (the 301 study) using Office Blood Pressure Measurements (OBPM) up to 13 weeks (see NOTE 2). The top-line results of this trial revealed a sustained reduction in blood pressure for naproxcinod, compared to baseline and naproxen. Additional results from this phase 3 trial are due to be presented on November 10, 2007, at the 71st annual meeting of the American College of Rheumatology.

"This ABPM trial was the first clinical study focusing specifically on naproxcinod's 24-hour blood pressure profile and its results reveal a clear difference compared to naproxen, which is one of the best-known cardiovascular NSAIDs," said Raymond Townsend, Professor of Medicine at the University of Pennsylvania, Philadelphia, who advised NicOx on the ABPM study. "The medical community recognizes the importance of blood pressure control in reducing the rate of serious cardiovascular events in elderly patients. These data add to the promising blood pressure results obtained by OBPM in the first 13-week phase 3 study and, if supported by the results of the ongoing 302 and 303 phase 3 studies, should contribute to naproxcinod becoming a valuable alternative to selective and non-selective NSAIDs for treating the signs and symptoms of osteoarthritis."

The presentation showed naproxcinod was well tolerated during the study. The number of subjects with at least one treatment related adverse event was low and evenly spread between naproxcinod and naproxen. There were no adverse events suggesting clinically significant hypotensive effects in either group.

Details of study design and ABPM monitoring

The trial was an 8-week, double-blind, randomized, cross-over study in which 131 male and female healthy volunteers were enrolled at 15 US clinical sites to receive either naproxcinod 750 mg bid, followed by naproxen 500 mg bid for 2 weeks, or the
'/>"/>

SOURCE NicOx S.A.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
2. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
5. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
6. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
7. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
8. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
9. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
10. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... (NYSE: RMD ), a pioneer and innovator in ... sleep apnea solutions specifically for women, is launching a new ... night,s sleep. The Better Sleep For Women ... just part of living a busy life. It will encourage ... health, essential to not only living an active lifestyle but ...
(Date:10/1/2014)... , Oct. 1, 2014  Varian Medical Systems ... will report results for the fourth quarter of fiscal ... Wednesday, October 22, 2014.  The news release will be ... at 2:00 p.m. PT.  The news release and a ... on the company website at: www.varian.com/investor .  To ...
(Date:10/1/2014)... , Oct. 1, 2014   Royal ... PHIA) today announced its eCareCoordinator and eCareCompanion telehealth ... Food and Drug Administration (FDA). A part of ... programs , eCareCoordinator and eCareCompanion are focused on ... first clinical applications to be available through the ...
Breaking Medicine Technology:ResMed Launches Initiative to Help Women Get Better Sleep 2ResMed Launches Initiative to Help Women Get Better Sleep 3Varian Medical Systems Schedules Fourth Quarter FY2014 News Release and Conference Call 2Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 2Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 3Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 4
... Jan. 11, 2011 Reportlinker.com announces that a ... catalogue: Novo Nordisk A/S: PharmaVitae ... Introduction This ... Novo Nordisk in the prescription pharmaceutical sector. The ...
... 11, 2011 Reportlinker.com announces that ... available in its catalogue: ... New pricing rules set to negatively ... internationally http://www.reportlinker.com/p0360217/Germany-Pharmaceutical-Market-Overview-–-New-pricing-rules-set-to-negatively-impact-drug-sales-both-domestically-and-internationally.html ...
Cached Medicine Technology:Reportlinker Adds Novo Nordisk A/S: PharmaVitae Profile 2Reportlinker Adds Germany Pharmaceutical Market Overview - New pricing rules set to negatively impact drug sales both domestically and internationally 2
(Date:10/1/2014)... beta-amyloid is strongly associated with Alzheimer,s disease; however, researchers ... is the causal agent of the onset and development ... is that beta-amyloid is not harmful when found in ... it self-assembles to form the so-called amyloid fibrils , ... alone, but with multiple ones because each aggregate of ...
(Date:10/1/2014)... by the Engineering and Physical Sciences Research Council ... UK,s vital industrial control systems which run, for ... and the rail network. , The research ... or malware infiltrating the systems behind our critical ... Trustworthy Industrial Control Systems (RITICS), based at Imperial ...
(Date:10/1/2014)... Familylifeinsurancequotes.org has released a new blog post ... , Senior citizens can qualify for affordable term ... seniors who are over 50 years old. Some term ... medical examination. , Term life insurance with a simplified ... qualify. Having life insurance during retirement is important for ...
(Date:10/1/2014)... Lifeinsurance-policy.com has released a new blog post explaining ... smokers. , Smoking will always have a negative impact ... best method to find affordable coverage. Insurance brokerage websites ... , Whole life insurance premiums will be fixed ... coverage is permanent, the initial rates are very ...
(Date:10/1/2014)... Farmington Company today announced it ... and visual identity helping brokers, consultants and companies ... to create greater benefit communication synergies. They unveiled ... empowering customers to better leverage Farmington Company’s industry-tested ... of the rebrand is the refreshed tagline: For ...
Breaking Medicine News(10 mins):Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Farmington Company Launches Rebrand and New Positioning 2
... new study shows men with prostate cancer who receive a ... reduce // the risk of recurrence after surgery may be ... showed men treated with androgen deprivation therapy (ADT) after prostate ... most common among women. Men who are older, smoke, or ...
... with the oral drug bosentan (Tracleer) has led to ... hypertension ( PAH) // . ,PAH is usually ... believed to cause the overproduction of endothelin, which increases ... This chronic obstruction leads to PAH, a condition that ...
... intense course of radiation after a lumpectomy may be ... on findings of a recent study. Standard treatment for ... weeks of radiation daily after undergoing surgery , however ... treatment is a major inconvenience leading them to choose ...
... a urinary tract infection can increase your chances of having ... few days, say researchers based on findings of a recent ... anytime we have an infection, to atherosclerosis, or clogging of ... of infections, some have speculated they, too, could aggravate the ...
... the existing drugs on the market are losing their ... bacteria hence researchers feel that the ocean is a ... ,More than 1 million microorganisms fill every milliliter of ... for some of our deadliest diseases. Many marine organisms ...
... J. Rutter, a well known scientist and accomplished businessman ... patent applications,has announced intention to set up a high ... of "Hemogenomics", which will be a marketing, selling and ... the sidelines of the BioAsia 2004 conference Bangalore on ...
Cached Medicine News:
Based on the clinically proven ACS MULTI-LINK Stent, ULTRA is a coronary stent system specifically designed for use in larger vessels. This innovative system utilizes a unique stent pattern to give y...
The MULTI-LINK RX PENTA Coronary Stent Systems with new ACCESS-LINK Stent Design are indicated for improving coronary luminal diameter....
Now available in 2.75-mm diameters, the S660 small vessel coronary stent expands your treatment options for accurate sizing and precision stenting....
The MULTI-LINK PIXEL Coronary Stent System was designed to address the challenges of small vessel treatment in patients with abrupt or threatened abrupt closure (ATC)....
Medicine Products: